ADVERSE EVENTS ASSOCIATED WITH mTOR INHIBITION: RESULTS FROM THE A2310 STUDY COMPARING EVEROLIMUS AND MMF IN DE NOVO HEART TRANSPLANT RECIPIENTS

被引：0
|
作者：
Poncelet, A. [1 ]
Musumeci, F. [2 ]
Fuchs, U. [3 ]
Mattei, M. F. [4 ]
Dong, G. [5 ]
Lopez, P. [6 ]
Hirt, S. [7 ]
机构：
[1] Catholic Univ Louvain, Fac Med, B-1200 Brussels, Belgium
[2] S Camillo Forlanini Hosp, Dept Cardiovasc Sci, Rome, Italy
[3] Ruhr Univ Bochum, Heart Ctr N Rhine Westphalia, Univ Hosp, Bad Oeynhausen, Germany
[4] Hop Brabois, Dept Cardiol & Transplantat, Nancy, France
[5] Novartis Pharmaceut, Dev, E Hanover, NJ USA
[6] Novartis Pharma AG, Clin Dev, Basel, Switzerland
[7] Univ Med Ctr Regensburg, Dept Cardiothorac Surg, Regensburg, Germany
来源：
TRANSPLANT INTERNATIONAL | 2011年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [31] Changes In Lipid Profiles Associated with Everolimus- and MMF-Based Immunosuppression Are Clinically Comparable in De Novo Cardiac Transplant Recipients
    Magnani, G.
    Almenar, L.
    Vigano, M.
    Maccberini, M.
    Pulpon, L. A.
    Musumeci, F.
    Gerosa, G.
    Lehmkuhl, H.
    Livi, U.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (02): : S90 - S90
  • [32] ASSESSMENT OF PROTEINURIA REPORTED AS ADVERSE EVENTS IN DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING AN EVEROLIMUS-BASED REGIMEN: 24-MONTH RESULTS FROM TRANSFORM
    Legendre, C.
    Buchler, M.
    Pernin, V.
    Berger, S. P.
    Oppenheimer, F.
    Wiseman, A.
    Viklicky, O.
    Russ, G. R.
    Danguilan, R.
    Basic-Jukic, N.
    Mor, E.
    Narvekar, P.
    Hernandez-Gutierrez, M. P.
    Bernhardt, P.
    Gharbi, H.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2020, 33 : 5 - 5
  • [33] Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study
    Spagnoletti, G.
    Salerno, M.
    Favi, E.
    Pedroso, J.
    Romagnoli, J.
    Citterio, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [34] Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomized Study EVERHEART
    Potena, L.
    Barberini, F.
    Boffini, M.
    Amarelli, C.
    Pellegrini, C.
    Livi, U.
    Masciocco, G.
    Faggian, G.
    Gerosa, G.
    Lilla, P.
    Marraudino, N.
    Porcu, M.
    Guarisco, R.
    Maccherini, M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (04): : S136 - S136
  • [35] EFFECT OF EARLY CONVERSION TO EVEROLIMUS ON CARDIOVASCULAR PARAMETERS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM THE ELEVATE STUDY
    Holdaas, Hallvard
    Van Der Giet, Markus
    De Fijter, Johan W.
    Speziale, Antonio
    Escrig, Cesar
    Junge, Guido
    Wang, Zailong
    Cruzado, Josep M.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 209 - 210
  • [36] Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis
    Eisen, H.
    Pauly, D.
    Starling, R.
    Lehmkuhl, H.
    Ross, H.
    Kfoury, A.
    Wang, S.
    Cantin, B.
    Van Bakel, A.
    Zuckermann, A.
    Lopez, P.
    Dong, G.
    Panis, C.
    Jiang, H.
    Cornu-Artis, C.
    Kobashigawa, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S25 - S26
  • [37] De Novo Heart Transplant Recipients at Increased Risk of Cardiac Allograft Vasculopathy: IVUS Analysis of Specific Subpopulations Treated with Everolimus Versus MMF
    Starling, R.
    Pauly, D.
    Wang, S.
    Cantin, B.
    Ross, H.
    Burton, J.
    Eisen, H. J.
    Keogh, A.
    Dong, G.
    Jiang, H.
    Cines, M.
    Lopez, P.
    Kobashigawa, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 132 - 132
  • [38] Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study
    Andreassen, A. K.
    Andersson, B.
    Gustafsson, F.
    Eiskjaer, H.
    Radegran, G.
    Gude, E.
    Jansson, K.
    Solbu, D.
    Karason, K.
    Arora, S.
    Dellgren, G.
    Gullestad, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (04) : 1238 - 1247
  • [39] Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM.
    Legendre, C.
    Berger, S.
    Oppenheimer, F.
    Wiseman, A.
    Steinberg, S.
    Viklicky, O.
    Russ, G.
    Danguilan, R.
    Basic-Jukic, N.
    Mor, E.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 693 - 694
  • [40] Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor
    Ferreira, Alexandra Nicolau
    Felipe, Claudia Rosso
    Cristelli, Marina
    Viana, Laila
    Mansur, Juliana
    de Paula, Mayara
    Wagner, Daniel
    de Marco, Renato
    Gerbase-DeLima, Maria
    Proenca, Henrique
    Aguiar, Wilson
    Medina-Pestana, Jose
    Tedesco-Silva Junior, Helio
    TRANSPLANT INTERNATIONAL, 2019, 32 (11) : 1127 - 1143
12345